Kyung-Jin Jang's Biography

Kyung-Jin Jang, Vice President, Emulate, Inc.

Kyung-Jin (KJ) Jang, Ph.D., is Vice President at Emulate, Inc. She has built a pioneering position within the Organs-on-Chips field through her multidisciplinary experiences. Before joining Emulate, she worked as a Postdoctoral Research Fellow at the Wyss Institute for Biologically Inspired Engineering at Harvard University. While at the Wyss, Jang and the Organs-on-Chips technology team developed multiple organ systems, including lung, kidney, liver, gut, and brain, and devised ways to link them together. She received her Ph.D. from the Interdisciplinary Program in Nano-Science and Technology at Seoul National University in South Korea, has earned recognition for academic excellence, and has received many honors in the field of Organs-on-Chips technology and toxicology. She has authored or co-authored 16 research publications and two book chapters.

Organs-on-Chips Technology: Applications in Safety Testing for Drug Discovery and Development

Tuesday, 15 October 2019 at 12:30

Add to Calendar ▼2019-10-15 12:30:002019-10-15 13:30:00Europe/LondonOrgans-on-Chips Technology: Applications in Safety Testing for Drug Discovery and DevelopmentOrgan-on-a-Chip World Congress 2019 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com

Preclinical animal models used to support selection of drug candidates for clinical trials can sometimes fail to predict potential human toxicity. This translation gap in safety data contributes to drug failures and attrition rates in the clinic. Here, we highlight the application of our microengineered Liver-Chip containing species-specific primary hepatocytes interfaced with liver sinusoidal endothelial cells, with or without Kupffer cells and hepatic stellate cells, cultured under physiological fluid flow for toxicity and safety assessment. We showed that our Liver-Chip detected diverse phenotypes of liver toxicity including hepatocellular injury, steatosis, cholestasis, and fibrosis as well as species-specific toxicities when treated with tool compounds. The adoption of Organs-on-Chips technology in the pharmaceutical industry may provide a useful platform for prediction of liver toxicity and inform human relevance of liver toxicities detected in animal studies to better determine safety and human risk.

Add to Calendar ▼2019-10-14 00:00:002019-10-15 00:00:00Europe/LondonOrgan-on-a-Chip World Congress 2019Organ-on-a-Chip World Congress 2019 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com

Corporate Sponsors